Literature DB >> 8643604

Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.

M D de Jong1, J Veenstra, N I Stilianakis, R Schuurman, J M Lange, R J de Boer, C A Boucher.   

Abstract

The association between human immunodeficiency virus type I (HIV-1) RNA load changes and the emergence of resistant virus variants was investigated in 24 HIV-1-infected asymptomatic persons during 2 years of treatment with zidovudine by sequentially measuring serum HIV-1 RNA load and the relative amounts of HIV-1 RNA containing mutations at reverse transcriptase (RT) codons 70 (K-->R), 41 (M-->L), and 215 (T-->Y/F). A mean maximum decline in RNA load occurred during the first month, followed by a resurgence between 1 and 3 months, which appeared independent of drug-resistance. Mathematical modeling suggests that this resurgence is caused by host-parasite dynamics, and thus reflects infection of the transiently increased numbers of CD4+ lymphocytes. Between 3 and 6 months of treatment, the RNA load returned to baseline values, which was associated with the emergence of virus containing a single lysine to arginine amino acid change at RT codon 70, only conferring an 8-fold reduction in susceptibility. Despite the relative loss of RNA load suppression, selection toward mutations at RT codons 215 and 41 continued. Identical patterns were observed in the mathematical model. While host-parasite dynamics and outgrowth of low-level resistant virus thus appear responsible for the loss of HIV-1 RNA load suppression, zidovudine continues to select for alternative mutations, conferring increasing levels of resistance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8643604      PMCID: PMC39275          DOI: 10.1073/pnas.93.11.5501

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

Authors:  C A Boucher; E O'Sullivan; J W Mulder; C Ramautarsing; P Kellam; G Darby; J M Lange; J Goudsmit; B A Larder
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

Review 2.  Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV.

Authors:  A R McLean; M A Nowak
Journal:  AIDS       Date:  1992-01       Impact factor: 4.177

3.  Modified protocol for DNA sequence analysis using Sequenase 2.0.

Authors:  R Schuurman; W Keulen
Journal:  Biotechniques       Date:  1991-02       Impact factor: 1.993

4.  Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.

Authors:  D Richman; C K Shih; I Lowy; J Rose; P Prodanovich; S Goff; J Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

5.  Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.

Authors:  B A Larder; P Kellam; S D Kemp
Journal:  AIDS       Date:  1991-02       Impact factor: 4.177

6.  Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

Authors:  M Tisdale; S D Kemp; N R Parry; B A Larder
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

7.  A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine.

Authors:  S Kaye; C Loveday; R S Tedder
Journal:  J Med Virol       Date:  1992-08       Impact factor: 2.327

8.  HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.

Authors:  C A Boucher; J M Lange; F F Miedema; G J Weverling; M Koot; J W Mulder; J Goudsmit; P Kellam; B A Larder; M Tersmette
Journal:  AIDS       Date:  1992-11       Impact factor: 4.177

9.  Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.

Authors:  P Kellam; C A Boucher; B A Larder
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

10.  Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection.

Authors:  M I Bukrinsky; T L Stanwick; M P Dempsey; M Stevenson
Journal:  Science       Date:  1991-10-18       Impact factor: 63.714

View more
  21 in total

1.  Adherence and drug resistance: predictions for therapy outcome.

Authors:  L M Wahl; M A Nowak
Journal:  Proc Biol Sci       Date:  2000-04-22       Impact factor: 5.349

Review 2.  New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.

Authors:  E Ravot; J Lisziewicz; F Lori
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

3.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

4.  The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Authors:  Robert W Shafer; Rami Kantor; Matthew J Gonzales
Journal:  AIDS Rev       Date:  2000       Impact factor: 2.500

5.  Frequency of drug-resistant variants of HIV-1 coexistent with wild-type in treatment-naive patients of India.

Authors:  Naresh Sachdeva; Shobha Sehgal; Sunil K Arora
Journal:  MedGenMed       Date:  2005-07-27

6.  Virus dynamics and drug therapy.

Authors:  S Bonhoeffer; R M May; G M Shaw; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

7.  Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.

Authors:  Zixin Hu; Françoise Giguel; Hiroyu Hatano; Patrick Reid; Jing Lu; Daniel R Kuritzkes
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

8.  3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants.

Authors:  E J Arts; M E Quiñones-Mateu; J L Albright; J P Marois; C Hough; Z Gu; M A Wainberg
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

9.  Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy.

Authors:  M Nijhuis; C A Boucher; P Schipper; T Leitner; R Schuurman; J Albert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

10.  Frequency of Drug-Resistant Variants of HIV-1 Coexistent With Wild-Type in Treatment-Naive Patients of India.

Authors:  Naresh Sachdeva; Shobha Sehgal; Sunil K Arora
Journal:  J Int AIDS Soc       Date:  2005-07-27       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.